Recent pro

Recent progress in the diagnosis and treatment of primary aldosteronism

Primary aldosteronism (PA) is caused by excessive secretion of aldosterone from the adrenal glands, with subsequent changes in the renin-angiotensin system. In Japan, chemiluminescent enzyme immunoassay is currently performed for aldosterone assay rather than the earlier method of radioimmunoassay. This change in aldosterone measurement methods has resulted in faster and more accurate measurement of blood aldosterone levels. Since 2019, esaxerenone, a mineralocorticoid receptor antagonist (MRA) with a non-steroidal skeleton, has been available in Japan for the treatment of hypertension. Esaxer

Using COVID-19-Positive Donor Hearts May Impact Post-Transplant Survival

Heart transplant recipients receiving organs from active COVID-19 positive donors may have an increased risk of death at 6 months and 1 year when compared with those receiving organs from patients who recently recovered from COVID-19 or COVID-19-nega...

The Use of Donor Hearts 50 Year-Old or Greater to Septuagenarians in Heart Transplantation

BACKGROUND The impact of using donors ≥50 year-old on the heart transplant outcomes of septuagenarians is unknown, which may have a potential to expand the donor pool. METHODS From Jan 2011 to Dec 2021, 817 septuagenarians received donor hea...


Spotify episodes

Apple podcasts

Google podcasts

Search:
Date
Filters:
Objective
6:01

Objective assessement of skin disease severity with the help of AI

Presenter: Maksym Breslavets
Dermatology
EADV Symposium 2023
What's new
8:09

What's new in treatment of breast cancer? - Highlights of ESMO BC 2023

Presenter: Matteo Lambertini
Oncology : Breast Cancer
ESMO Breast Cancer 2023
Hot topics
15:11

Hot topics in melanoma management

Presenter: Paolo A. Ascierto
Oncology
EADO 2023
Functional
10:33

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
Oncology
AACR 2023
The first
14:14

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Oncology
AACR 2023
Current is
13:39

Current issues in the treatment of schizophrenia

Presenter: Istvan Bitter
Psychiatry
EPA 2023
Highlights
10:47

Highlights of EPA 2023

Presenter: Peter Falkai
Psychiatry
EPA 2023
The Risk o
5:25

The Risk of Early Recurrent MI: What is the Role of Cholesterol Efflux and ApoA-I?

Presenter: Eliot A. Brinton
Cardiology
ACC 2023
Bempedoic
5:48

Bempedoic Acid Improves Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

Presenter: Eliot A. Brinton
Cardiology
ACC 2023
How to inc
6:19

How to increase prescription of evidence-based therapies in adults with T2D and ASCVD? - The COORDINATE-Diabetes Study

Presenter: Neha Pagidipati
Cardiology
ACC 2023
The FREEDO
6:42

The FREEDOM COVID Anticoagulation Strategy Randomized Trial

Presenter: Gregg Stone
Cardiology
ACC 2023
Minimally
7:09

Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery - UK Mini Mitral Trial

Presenter: Enoch Akowuah
Cardiology
ACC 2023
Can Patien
3:56

Can Patients with Hypertrophic Cardiomyopathy do Vigorous Exercise? - A Multinational Lifestyle And Exercise Study

Presenter: Rachel Lampert
Cardiology
ACC 2023
Efficacy a
3:31

Efficacy and Safety of Oral PCSK9 Inhibitor, MK-0616 in the Treatment of Hypercholesterolemia

Presenter: Eliot A. Brinton
Cardiology
ACC 2023
Transcathe
4:33

Transcatheter Edge-to-Edge Repair of Functional Mitral Regurgitation in Heart Failure - The COAPT Trial

Presenter: Gregg Stone
Cardiology
ACC 2023
Elevated L
16:07

Elevated Lipoprotein(a) as a Risk Enhancing Factor for Atherosclerotic Cardiovascular Disease

Presenter: Nathan D. Wong
Cardiology
ACC 2023
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The Omega-
1:17

The Omega-3 Mystery: New Evidence Supports the Therapeutic Value of EPA

Presenter: Eliot A. Brinton
Cardiology
The issue
1:15

The issue of adjuvant vs neoadjuvant treatment

Presenter: Paolo A. Ascierto
Oncology
The treatm
1:19

The treatment sequence in metastatic melanoma

Presenter: Paolo A. Ascierto
Oncology
LMWH use i
1:12

LMWH use in pregnancy: The ALPINE trial

Presenter: Saskia Middeldorp
Hematology
Functional
1:19

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
Oncology
The first
1:10

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Oncology
Elevated L
1:18

Elevated Lipoprotein(a) as a Risk Enhancing Factor for Atherosclerotic Cardiovascular Disease

Presenter: Nathan D. Wong
Cardiology
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato
Oncology
Treatment
3:27

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Cardiology